Athenex, a US-China biopharma, filed to raise $100 million in a US IPO on the NASDAQ exchange. Athenex has developed a platform that develops oral formulations of existing chemotherapies. Its lead product is an oral form of paclitaxel (Oraxol), which it is developing along with oral irinotecan, docetaxel and topotecan. In 2016, Athenex raised $200 million from New York State -- the company is headquartered in Buffalo, New York -- in return for a promise to provide manufacturing jobs. One year earlier, Athenex struck a similar deal with Chongqing, China to build two manufacturing facilities there.
Source: ChinaBio Today
Please to leave a comment.